The H1 results are promising, confirming the attractiveness of market dynamics
04/09/25 -"bioMerieux’s H1 profitability surpassed expectations. Topline growth was driven by robust performance across both segments. However, weakness in China is likely to limit topline performance in ..."
Pages
71
Language
English
Published on
04/09/25
You may also be interested by these reports :
05/09/25
Bastide reported FY24/25 revenue in line with guidance and our forecast. The more technical business activities remain the primary driver of organic ...
05/09/25
Since we last pushed Philips’ (Buy; Netherlands) investment case in January 2024, its share price performance has been glaringly ahead of the MedTech ...
04/09/25
bioMerieux’s H1 profitability surpassed expectations. Topline growth was driven by robust performance across both segments. However, weakness in ...
29/08/25
Despite being a dominant player in the ophthalmology space, Alcon has been reeling under the pressure of slower than expected market growth this ...